MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- LUPIN - ADCOCK INGRAM (S. Africa)
LUPIN vs ADCOCK INGRAM (S. Africa) - Comparison Results
LUPIN Change
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 LUPIN  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| LUPIN Mar-20 |
ADCOCK INGRAM Jun-14 |
LUPIN/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 882 | 383 | - | |
| Low | Rs | 505 | 276 | - | |
| Sales per share (Unadj.) | Rs | 339.4 | 113.9 | - | |
| Earnings per share (Unadj.) | Rs | -5.9 | -28.7 | - | |
| Cash flow per share (Unadj.) | Rs | 15.5 | -23.8 | - | |
| Dividends per share (Unadj.) | Rs | 6.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.9 | 0 | - | |
| Book value per share (Unadj.) | Rs | 276.7 | 89.4 | - | |
| Shares outstanding (eoy) | m | 453.00 | 168.78 | - | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.0 | 2.9 | 70.6% | |
| Avg P/E ratio | x | -116.6 | -11.5 | 1,015.7% | |
| P/CF ratio (eoy) | x | 44.8 | -13.9 | -323.6% | |
| Price / Book Value ratio | x | 2.5 | 3.7 | 68.0% | |
| Dividend payout | % | -100.9 | 0 | - | |
| Avg Mkt Cap | Rs m | 314,201 | 55,608 | 565.0% | |
| No. of employees | `000 | 18.3 | 4.3 | 426.3% | |
| Total wages/salary | Rs m | 29,868 | 3,490 | 855.8% | |
| Avg. sales/employee | Rs Th | 8,400.6 | 4,476.9 | 187.6% | |
| Avg. wages/employee | Rs Th | 1,632.0 | 813.0 | 200.7% | |
| Avg. net profit/employee | Rs Th | -147.2 | -1,128.1 | 13.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 153,748 | 19,219 | 800.0% | |
| Other income | Rs m | 4,838 | 135 | 3,594.4% | |
| Total revenues | Rs m | 158,585 | 19,354 | 819.4% | |
| Gross profit | Rs m | 24,849 | -3,331 | -746.1% | |
| Depreciation | Rs m | 9,702 | 829 | 1,169.7% | |
| Interest | Rs m | 3,630 | 521 | 697.2% | |
| Profit before tax | Rs m | 16,355 | -4,546 | -359.8% | |
| Minority Interest | Rs m | 4 | -13 | -30.8% | |
| Prior Period Items | Rs m | 39 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -7,521 | 0 | - | |
| Tax | Rs m | 11,571 | 284 | 4,073.4% | |
| Profit after tax | Rs m | -2,694 | -4,843 | 55.6% | |
| Gross profit margin | % | 16.2 | -17.3 | -93.3% | |
| Effective tax rate | % | 70.8 | -6.2 | -1,132.3% | |
| Net profit margin | % | -1.8 | -25.2 | 7.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 154,132 | 14,076 | 1,095.0% | |
| Current liabilities | Rs m | 92,252 | 7,920 | 1,164.8% | |
| Net working cap to sales | % | 40.2 | 32.0 | 125.6% | |
| Current ratio | x | 1.7 | 1.8 | 94.0% | |
| Inventory Days | Days | 82 | 111 | 74.0% | |
| Debtors Days | Days | 129 | 124 | 104.3% | |
| Net fixed assets | Rs m | 89,082 | 8,205 | 1,085.7% | |
| Share capital | Rs m | 906 | 89 | 1,015.3% | |
| Net worth | Rs m | 125,367 | 15,085 | 831.1% | |
| Long term debt | Rs m | 17,933 | 5,301 | 338.3% | |
| Total assets | Rs m | 249,839 | 28,497 | 876.7% | |
| Interest coverage | x | 5.5 | -7.7 | -71.2% | |
| Debt to equity ratio | x | 0.1 | 0.4 | 40.7% | |
| Sales to assets ratio | x | 0.6 | 0.7 | 91.2% | |
| Return on assets | % | 0.4 | -15.2 | -2.5% | |
| Return on equity | % | -2.1 | -32.1 | 6.7% | |
| Return on capital | % | 8.7 | -19.8 | -44.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 14,688 | 1,640 | 895.4% | |
| From Investments | Rs m | 11,070 | -504 | -2,197.7% | |
| From Financial Activity | Rs m | -8,906 | 4,811 | -185.1% | |
| Net Cashflow | Rs m | 16,853 | 5,948 | 283.3% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.28 Rs / ZAR
Compare LUPIN With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare LUPIN With: FDC BIOCON WYETH DISHMAN PHARMA IPCA LABS
Today's Market
Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Related Views On News
LUPIN 2019-20 Annual Report Analysis (Annual Result Update)
Dec 7, 2020 | Updated on Dec 7, 2020Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.
LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)
Aug 18, 2020 | Updated on Aug 18, 2020For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.
LUPIN 2018-19 Annual Report Analysis (Annual Result Update)
Jul 18, 2019 | Updated on Jul 18, 2019Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
